DVDwarakanathan Vignesh

Dwarakanathan Vignesh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dwarakanathan Vignesh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Global Prevalence of Adherence to Gluten-Free Diet in Patients With Celiac Disease: A Systematic Review and Meta-Analysis

    by Shubham Mehta, Ashish Chauhan, Dwarakanathan Vignesh, Ritik Mahaveer Goyal, Raghavendra Puri, Vishwesh Bharadiya, Suyasha Gupta, Pavit Singh, Ankit Agarwal, Aditya Vikram Pachisia, et al.

    INTRODUCTION: Strict and life-long gluten-free diet (GFD) is the standard of care for patients with celiac disease (CeD). Maintenance of adherence to GFD is the key to the success of GFD; however, a proportion of patients are unable to maintain strict adherence to GFD. METHODS: We performed a systematic review and meta-analysis to estimate the pooled prevalence of adherence of GFD, as assessed by celiac dietary adherence test, BIAGI score, standardized dietitian evaluation or self-reported adherence to GFD, in patients with CeD after at least 1 year of initiating GFD. Electronic reference databases were searched from January 1, 1990 to April 30, 2025. Overall, 69 studies including 27,641 subjects were found eligible for pooling estimates by objective assessment methods. The pooled effect size (95% confidence interval [CI]) was calculated using a random effect model. RESULTS: Most of the studies had low risk of bias and there was no publication bias. The pooled prevalence of adherence to GFD as assessed by objective methods of assessment and self-reported adherence were 64% (95% CI 59%–69%) and 74% (95% CI 69%–79%), respectively. Specifically adherence rates were 65% (95% CI 57%–73%) with standardized dietitian evaluation, 57% (95% CI 50%–64%) with celiac dietary adherence test and 75% (95% CI 65%–83%) with BIAGI score. Highest adherence rates were reported from European and North American countries. There was no significant difference in the adherence rates with time or age of the participants. On univariate metaregression, method of assessment of adherence affected the rate of adherence to GFD. DISCUSSION: One in 3 patients with CeD is unable to maintain a good adherence to GFD. There is need to develop strategies to improve the adherence to GFD.


  • Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet

    by Aditya Vikram Pachisia, Ankit Agarwal, Shubham Mehta, Alka Kumari, Vignesh Dwarakanathan, Sonu Sharma, Sambuddha Kumar, Lalita Mehra, Rimlee Dutta, Prasenjit Das, et al.

    INTRODUCTION: Liver involvement is common in celiac disease (CeD), and up to 4.6% of patients with cryptogenic cirrhosis have CeD. We investigated the prevalence of CeD in patients with cryptogenic cirrhosis and assessed liver-related outcomes in them on GFD when compared with a propensity score–matched cohort of patients with cryptogenic cirrhosis without CeD. METHODS: Consecutive patients with cryptogenic cirrhosis were screened for CeD using IgA anti–tissue transglutaminase antibody (anti-tTG) followed by antiendomysial antibody and duodenal and liver biopsies, on which IgA/anti-tTG colocalization studies were performed. These patients and a cohort of patients with cryptogenic cirrhosis without CeD (1:4 CeD: no CeD matched using propensity score matched for age, sex, Child–Turcotte–Pugh [CTP] and model for end-stage liver disease [MELD]) were initiated on GFD plus standard of care and standard of care, respectively, and followed up for liver-related outcomes for 1 year. RESULTS: Of 232 patients with cryptogenic cirrhosis, 14 had high anti-tTG Ab (16.9 ± 10.5 fold rise), with 9 antiendomysial antibody–positive and 11 (4.7%) biopsy-proven CeD. IgA/anti-tTG Ab colocalization was demonstrated in 7/8 liver and 10/11 duodenal biopsies. Patients with cryptogenic cirrhosis with definite CeD (n = 11) and matched cohort without CeD (n = 44) were similar at baseline (age: 31.3 ± 7.7 vs 31.8 ± 9.3 years; 5 [45.5%] vs 15 [34.1%] females; MELDNa 9 [interquartile-range: 8–15.5] vs 12 [9–15]; CTP 7 [6–7.5] vs 6 [5.75–7]). Patients with CeD on GFD improved significantly on follow-up compared with those without CeD (follow-up MELDNa: 9 [7.5–10.5] vs 18.5 [12-20]; P = 0.001 and follow-up CTP: 5 [5-5] vs 8 [7–9]; P < 0.001) with less frequent further decompensations and similar mortality (9.1% vs 18.2%; P = 0.67). DISCUSSION: Approximately 4.7% of patients with cryptogenic cirrhosis have biopsy-proven CeD, and their liver-related outcomes improve with GFD.